Astrazeneca (AZN) Acquisitions (2010 - 2025)

Astrazeneca has reported Acquisitions for 14 years, with the latest figure at -$6.0 million in Q4 2025.

• On a quarterly basis, Acquisitions changed N/A year-over-year to -$6.0 million in Q4 2025; TTM through Dec 2025 was -$2.1 billion, a 25.98% increase from a year earlier, with the FY2025 full-year figure at -$66.0 million, up 97.62% from the prior year.
• Acquisitions was -$6.0 million for Q4 2025 at Astrazeneca, up from -$2.0 billion in the prior quarter.
• The five-year high for Acquisitions was -$6.0 million in Q4 2025, with the low at -$2.0 billion in Q2 2024.
• Average Acquisitions over 3 years is -$741.5 million, with a median of -$457.5 million recorded in 2023.
• The largest YoY upside for Acquisitions was 284.13% in 2024 against a maximum downside of 284.13% in 2024.
• Over 3 years, Acquisitions stood at -$189.0 million in 2023, then tumbled by 982.01% to -$2.0 billion in 2024, then jumped by 99.71% to -$6.0 million in 2025.
• The last three Acquisitions figures came in at -$6.0 million (Q4 2025), -$2.0 billion (Q2 2024), and -$726.0 million (Q1 2024), per Business Quant data.